Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile

Bibliography

• Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5
   PubMed Web of Science ®Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007;5:505-17
   PubMed Web of Science ®Google Scholar
• Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723-39
   PubMed Web of Science ®Google Scholar
• Dougan G, Hormaeche C. How bacteria and their products provide clues to vaccine and adjuvant development. Vaccine 2006;24(Suppl 2):S2-9
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-97
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007;13:460-69
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006;124:849-63
   PubMed Web of Science ®Google Scholar
• Burdin N, Guy B, Moingeon P. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 2004;18:79-93
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-36
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18
   PubMed Web of Science ®Google Scholar
• Joffre O, Nolte MA, Sporri R, Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009;227:234-47
   PubMed Web of Science ®Google Scholar
• Randolph GJ, Jakubzick C, Qu C. Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol 2008;20:52-60
   PubMed Web of Science ®Google Scholar
• van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006;27:49-55
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006;442:39-44
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-21
   PubMed Web of Science ®Google Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54(Pt 1):1-13
   PubMedGoogle Scholar
• Brewer JM. (How) do aluminium adjuvants work? Immunol Lett 2006;102:10-15
   PubMed Web of Science ®Google Scholar
• Glenny AT, Buttle GAH, Stevens MF. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea pigs: toxoid precipitated with alum. J Pathol 1931;34:267-75
   Google Scholar
• Ramon G. Procedes pour accroitre la production des antitoxines. Ann Inst Pasteur 1926;40:1-10
   Google Scholar
• Hogen Esch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002;20(Suppl 3):S34-9
   PubMedGoogle Scholar
• Lindblad EB. Aluminium adjuvants-in retrospect and prospect. Vaccine 2004;22:3658-68
   PubMed Web of Science ®Google Scholar
• Morefield GL, Sokolovska A, Jiang D, Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005;23:1588-95
   PubMed Web of Science ®Google Scholar
• Kool M, Soullie T, van Nimwegen M, Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205:869-82
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O'Connor W, Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453:1122-26
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Kool M, Willart MAM, Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21:23-9
   PubMed Web of Science ®Google Scholar
• Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007;178:5271-76
   PubMed Web of Science ®Google Scholar
• Marrack P, McKee AS, Munks, MW. Towards an understanding of the adjuvant action of aluminium. Nat.Rev.Immunol 2009;9:287-93
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, New horizons in adjuvants for vaccine development. Trends Immunol 2009;30:23-32
   PubMed Web of Science ®Google Scholar
• Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009;27:3331-34
   PubMed Web of Science ®Google Scholar
• Hirschfeld M, Ma Y, Weis JH, Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000;165:618-22
   PubMed Web of Science ®Google Scholar
• Tapping RI, Akashi S, Miyake K, Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000;165:5780-87
   PubMed Web of Science ®Google Scholar
• Baldridge JR, McGowan P, Evans JT, Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;4:1129-38
   PubMed Web of Science ®Google Scholar
• Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008;65:3231-40
   PubMed Web of Science ®Google Scholar
• Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1982;257:11808-15
   PubMed Web of Science ®Google Scholar
• Ismaili J, Rennesson J, Aksoy E, Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002;168:926-32
   PubMed Web of Science ®Google Scholar
• Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003;71:2498-507
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14
   PubMed Web of Science ®Google Scholar
• Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007;6:133-40
   PubMed Web of Science ®Google Scholar
• Garcon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. In: Schijns V, O'Hagan D, editors, Immunopotentiators in Modern Vaccines. Elsevier Academic Press, London; 2006. p. 161-77
   Google Scholar
• Bosch FX, Burchell AN, Schiffman M, Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10):K1-16
   PubMed Web of Science ®Google Scholar
• Liaw KL, Hildesheim A, Burk RD, A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Schiffman M, Herrero R, Desalle R, The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84
   PubMed Web of Science ®Google Scholar
• de Villiers EM, Fauquet C, Broker TR, Classification of papillomaviruses. Virology 2004;324:17-27
   PubMed Web of Science ®Google Scholar
• Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008;110:S18-25
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24:S11-25
   Web of Science ®Google Scholar
• Munoz N, Bosch FX, Castellsague X, Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85
   PubMed Web of Science ®Google Scholar
• Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32(Suppl 1):S7-15
   PubMed Web of Science ®Google Scholar
• Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89:213-28
   PubMed Web of Science ®Google Scholar
• Passmore J-AS, Milner M, Denny L, Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia. Immunology 2006;119:507-14
   PubMed Web of Science ®Google Scholar
• Ho GY, Studentsov YY, Bierman R, Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-16
   PubMed Web of Science ®Google Scholar
• Ressing ME, van Driel WJ, Celis E, Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996;56:582-8
   PubMed Web of Science ®Google Scholar
• Breitburd F, Kirnbauer R, Hubbert NL, Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63
   PubMed Web of Science ®Google Scholar
• Christensen ND, Reed CA, Cladel NM, Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960-5
   PubMed Web of Science ®Google Scholar
• Suzich JA, Ghim S-J, Palmer-Hill FJ, Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-57
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008;110:S1-10
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N, Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-84
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P, Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-49
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, AS04, an Aluminum Salt- and TLR-4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183:6186-97
   PubMed Web of Science ®Google Scholar
• Fazilleau N, Mark L, Heyzer-Williams LJ, Follicular helper T cells: lineage and location. Immunity 2009;30:324-35
   PubMed Web of Science ®Google Scholar
• Malherbe L, Mark L, Fazilleau N, Vaccine adjuvants alter TCR-based selection thresholds. Immunity 2008;28:698-709
   PubMed Web of Science ®Google Scholar
• Fazilleau N, Heyzer-Williams LJ, Rosen H, The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat Immunol 2009;10:375-84
   PubMed Web of Science ®Google Scholar
• Ruprecht CR, Lanzavecchia, A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006;36:810-16
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298:2199-202
   PubMed Web of Science ®Google Scholar
• Bourke E, Bosisio D, Golay J, The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003;102:956-63
   PubMed Web of Science ®Google Scholar
• Colonna M. Toll-like receptors and IFN-alpha: partners in autoimmunity. J Clin Invest 2006;116:2319-22
   PubMed Web of Science ®Google Scholar
• Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-35
   PubMed Web of Science ®Google Scholar
• Zanin-Zhorov A, Tal-Lapidot G, Cahalon L, Cutting edge: T cells respond to lipopolysaccharide innately via TLR4 signaling. J Immunol 2007;179:41-4
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005;438:364-68
   PubMed Web of Science ®Google Scholar
• Schwarz T, Rivera M, Valencia A, Long-term safety and immunogenicity of a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in girls aged 10 – 14 years: 36-month follow-up. Pediatr Infect Dis J 2009;28:e197
   Google Scholar
• Romanowski B, de Borba PC, Naud PS, Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G, Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40:564-71
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Spaczynski M, Schneider A, Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-87
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18 – 45 years. Hum Vaccin 2009;5:705-19
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35
   PubMed Web of Science ®Google Scholar
• Descamps D, Hardt K, Spiessens B, Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009;5:332-40
   PubMed Web of Science ®Google Scholar
• Verstraeten T, Descamps D, David MP, Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008;26:6630-8
   PubMed Web of Science ®Google Scholar